GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Access Bio Inc (XKRX:950130) » Definitions » 3-Year Book Growth Rate

Access Bio (XKRX:950130) 3-Year Book Growth Rate : 94.40% (As of Mar. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Access Bio 3-Year Book Growth Rate?

Access Bio's Book Value per Share for the quarter that ended in Mar. 2024 was ₩17,908.50.

During the past 12 months, Access Bio's average Book Value per Share Growth Rate was -5.90% per year. During the past 3 years, the average Book Value per Share Growth Rate was 94.40% per year. During the past 5 years, the average Book Value per Share Growth Rate was 94.50% per year. During the past 10 years, the average Book Value per Share Growth Rate was 22.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 12 years, the highest 3-Year average Book Value per Share Growth Rate of Access Bio was 189.60% per year. The lowest was -30.00% per year. And the median was 11.90% per year.


Competitive Comparison of Access Bio's 3-Year Book Growth Rate

For the Diagnostics & Research subindustry, Access Bio's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Access Bio's 3-Year Book Growth Rate Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Access Bio's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Access Bio's 3-Year Book Growth Rate falls into.



Access Bio 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.


Access Bio  (XKRX:950130) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.


Access Bio 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Access Bio's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Access Bio (XKRX:950130) Business Description

Traded in Other Exchanges
N/A
Address
65 Clyde Road, Suite A, Somerset, NJ, USA, 08873
Access Bio Inc is a United States based bio company engaged in the research, development, and manufacturing of in vitro rapid diagnostic tests, biosensor, and molecular diagnostic products. The products are for the prevention and early diagnosis of infectious diseases. The company's core in vitro-diagnostic technology includes immunochemical, biochemical and molecular products. The company offers products for Rapid Diagnostic Tests including CareStart G6PD RDT, CareStart Malaria, CareStart Dengue Combo, and CareStart Scrub Typhus IgM; Biosensors product includes CareStart G6PD Biosensor, and Molecular Diagnostics products include CareStart HPV and CareStart CAH.

Access Bio (XKRX:950130) Headlines

No Headlines